Identification of pharmacological targets in Amyotrophic lateral sclerosis through genomic analysis of deregulated genes and pathways

Current Genomics

Volumn 13, Issue 4, 2012, Pages 321-333

  Paratore, Sabrina ^a,b   Pezzino, Salvatore ^a   Cavallaro, Sebastiano ^a,b  

^a INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

ALS; Drug; Networks; Pathway; Pharmacogenomics; Target

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; ATPASE SODIUM POTASSIUM TRANSPORTING ALPHA 3 POLYPEPTIDE; CILOSTAZOL; METALLOTHIONEIN; POTASSIUM VOLTAGE GATED CHANNEL SUBFAMILY C MEMBER 2; PROTEIN; SOLUTE CARRIER FAMILY 12 MEMBER 5; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CELL COMPONENT; CYTOSKELETON; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENOMICS; HUMAN; INTERMITTENT CLAUDICATION; LIFESTYLE; MICROARRAY ANALYSIS; NEUROFILAMENT; NONHUMAN; PATHOGENESIS; PROTEIN PROTEIN INTERACTION; REVIEW; SYSTEMS BIOLOGY; TRANSCRIPTOMICS;

EID: 84862590657     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/138920212800793366     Document Type: Review

References (99)

1. Mitchell, J.D.; Borasio, G.D. Amyotrophic lateral sclerosis. Lancet, 2007, 369(9578), 2031-2041.
2. Aranda, B.; Achuthan, P.; Alam-Faruque, Y.; Armean, I.; Bridge, A.; Derow, C.; Feuermann, M.; Ghanbarian, A.T.; Kerrien, S.; Khadake, J.; Kerssemakers, J.; Leroy, C.; Menden, M.; Michaut, M.; Montecchi-Palazzi, L.; Neuhauser, S.N.; Orchard, S.; Perreau, V.; Roechert, B.; van Eijk, K.; Hermjakob, H. The IntAct molecular interaction database in 2010. Nucleic Acids Res., 2010, 38(Database issue), D525-531.
3. Beghi, E.; Logroscino, G.; Chio, A.; Hardiman, O.; Mitchell, D.; Swingler, R.; Traynor, B.J. The epidemiology of ALS and the role of population-based registries. Biochim. Biophys. Acta, 2006, 1762(11-12), 1150-1157.
4. Miller, R.G.; Mitchell, J.D.; Moore, D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev., 2012, 3, CD001447.
5. Pasinelli, P.; Brown, R.H. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat. Rev. Neurosci., 2006, 7(9), 710-723.
6. Rosen, D.R. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 1993, 364(6435), 362.
7. Chen, Y.Z.; Bennett, C.L.; Huynh, H.M.; Blair, I.P.; Puls, I.; Irobi, J.; Dierick, I.; Abel, A.; Kennerson, M.L.; Rabin, B.A.; Nicholson, G.A.; Auer-Grumbach, M.; Wagner, K.; De Jonghe, P.; Griffin, J.W.; Fischbeck, K.H.; Timmerman, V.; Cornblath, D.R.; Chance, P.F. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. J. Hum. Genet., 2004, 74(6), 1128-1135.
8. Nishimura, A.L.; Mitne-Neto, M.; Silva, H.C.; Richieri-Costa, A.; Middleton, S.; Cascio, D.; Kok, F.; Oliveira, J.R.; Gillingwater, T.; Webb, J.; Skehel, P.; Zatz, M. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet., 2004, 75(5), 822-831.
9. Hadano, S.; Hand, C.K.; Osuga, H.; Yanagisawa, Y.; Otomo, A.; Devon, R.S.; Miyamoto, N.; Showguchi-Miyata, J.; Okada, Y.; Singaraja, R.; Figlewicz, D.A.; Kwiatkowski, T.; Hosler, B.A.; Sagie, T.; Skaug, J.; Nasir, J.; Brown, R.H., Jr.; Scherer, S.W.; Rouleau, G.A.; Hayden, M.R.; Ikeda, J.E. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet., 2001, 29(2), 166-173.
10. Yang, Y.; Hentati, A.; Deng, H.X.; Dabbagh, O.; Sasaki, T.; Hirano, M.; Hung, W.Y.; Ouahchi, K.; Yan, J.; Azim, A.C.; Cole, N.; Gascon, G.; Yagmour, A.; Ben-Hamida, M.; Pericak-Vance, M.; Hentati, F.; Siddique, T. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet., 2001, 29(2), 160-165.
11. Orlacchio, A.; Babalini, C.; Borreca, A.; Patrono, C.; Massa, R.; Basaran, S.; Munhoz, R.P.; Rogaeva, E.A.; St George-Hyslop, P.H.; Bernardi, G.; Kawarai, T. SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain, 2010, 133(Pt 2), 591-598.
12. Greenway, M.J.; Andersen, P.M.; Russ, C.; Ennis, S.; Cashman, S.; Donaghy, C.; Patterson, V.; Swingler, R.; Kieran, D.; Prehn, J.; Morrison, K.E.; Green, A.; Acharya, K.R.; Brown, R.H., Jr.; Hardiman, O. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat. Genet., 2006, 38(4), 411-413.
13. Chow, C.Y.; Zhang, Y.; Dowling, J.J.; Jin, N.; Adamska, M.; Shiga, K.; Szigeti, K.; Shy, M.E.; Li, J.; Zhang, X.; Lupski, J.R.; Weisman, L.S.; Meisler, M.H. Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature, 2007, 448(7149), 68-72.
14. Maruyama, H.; Morino, H.; Ito, H.; Izumi, Y.; Kato, H.; Watanabe, Y.; Kinoshita, Y.; Kamada, M.; Nodera, H.; Suzuki, H.; Komure, O.; Matsuura, S.; Kobatake, K.; Morimoto, N.; Abe, K.; Suzuki, N.; Aoki, M.; Kawata, A.; Hirai, T.; Kato, T.; Ogasawara, K.; Hirano, A.; Takumi, T.; Kusaka, H.; Hagiwara, K.; Kaji, R.; Kawakami, H. Mutations of optineurin in amyotrophic lateral sclerosis. Nature, 2010, 465(7295), 223-226.
15. Majoor-Krakauer, D.; Willems, P.J.; Hofman, A. Genetic epidemiology of amyotrophic lateral sclerosis. Clin. Genet., 2003, 63(2), 83-101.
16. Kabashi, E.; Valdmanis, P.N.; Dion, P.; Spiegelman, D.; McConkey, B.J.; Vande Velde, C.; Bouchard, J.P.; Lacomblez, L.; Pochigaeva, K.; Salachas, F.; Pradat, P.F.; Camu, W.; Meininger, V.; Dupre, N.; Rouleau, G.A. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet., 2008, 40(5), 572-574.
17. Vance, C.; Rogelj, B.; Hortobagyi, T.; De Vos, K.J.; Nishimura, A.L.; Sreedharan, J.; Hu, X.; Smith, B.; Ruddy, D.; Wright, P.; Ganesalingam, J.; Williams, K.L.; Tripathi, V.; Al-Saraj, S.; Al-Chalabi, A.; Leigh, P.N.; Blair, I.P.; Nicholson, G.; de Belleroche, J.; Gallo, J.M.; Miller, C.C.; Shaw, C.E. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science, 2009, 323(5918), 1208-1211.
18. Schymick, J.C.; Scholz, S.W.; Fung, H.C.; Britton, A.; Arepalli, S.; Gibbs, J.R.; Lombardo, F.; Matarin, M.; Kasperaviciute, D.; Hernandez, D.G.; Crews, C.; Bruijn, L.; Rothstein, J.; Mora, G.; Restagno, G.; Chio, A.; Singleton, A.; Hardy, J.; Traynor, B.J. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol., 2007, 6(4), 322-328.
19. van Es, M.A.; Veldink, J.H.; Saris, C.G.; Blauw, H.M.; van Vught, P.W.; Birve, A.; Lemmens, R.; Schelhaas, H.J.; Groen, E.J.; Huisman, M.H.; van der Kooi, A.J.; de Visser, M.; Dahlberg, C.; Estrada, K.; Rivadeneira, F.; Hofman, A.; Zwarts, M.J.; van Doormaal, P.T.; Rujescu, D.; Strengman, E.; Giegling, I.; Muglia, P.; Tomik, B.; Slowik, A.; Uitterlinden, A.G.; Hendrich, C.; Waibel, S.; Meyer, T.; Ludolph, A.C.; Glass, J.D.; Purcell, S.; Cichon, S.; Nothen, M.M.; Wichmann, H.E.; Schreiber, S.; Vermeulen, S.H.; Kiemeney, L.A.; Wokke, J.H.; Cronin, S.; McLaughlin, R.L.; Hardiman, O.; Fumoto, K.; Pasterkamp, R.J.; Meininger, V.; Melki, J.; Leigh, P.N.; Shaw, C.E.; Landers, J.E.; Al-Chalabi, A.; Brown, R.H., Jr.; Robberecht, W.; Andersen, P.M.; Ophoff, R.A.; van den Berg, L.H. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat. Genet., 2009, 41(10), 1083-1087.
20. Laaksovirta, H.; Peuralinna, T.; Schymick, J.C.; Scholz, S.W.; Lai, S.L.; Myllykangas, L.; Sulkava, R.; Jansson, L.; Hernandez, D.G.; Gibbs, J.R.; Nalls, M.A.; Heckerman, D.; Tienari, P.J.; Traynor, B.J. Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol., 2010, 9(10), 978-985.
21. Shatunov, A.; Mok, K.; Newhouse, S.; Weale, M.E.; Smith, B.; Vance, C.; Johnson, L.; Veldink, J.H.; van Es, M.A.; van den Berg, L.H.; Robberecht, W.; Van Damme, P.; Hardiman, O.; Farmer, A.E.; Lewis, C.M.; Butler, A.W.; Abel, O.; Andersen, P.M.; Fogh, I.; Silani, V.; Chio, A.; Traynor, B.J.; Melki, J.; Meininger, V.; Landers, J.E.; McGuffin, P.; Glass, J.D.; Pall, H.; Leigh, P.N.; Hardy, J.; Brown, R.H., Jr.; Powell, J.F.; Orrell, R.W.; Morrison, K.E.; Shaw, P.J.; Shaw, C.E.; Al-Chalabi, A. Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol., 2010, 9(10), 986-994.
22. Van Deerlin, V.M.; Sleiman, P.M.; Martinez-Lage, M.; Chen-Plotkin, A.; Wang, L.S.; Graff-Radford, N.R.; Dickson, D.W.; Rademakers, R.; Boeve, B.F.; Grossman, M.; Arnold, S.E.; Mann, D.M.; Pickering-Brown, S.M.; Seelaar, H.; Heutink, P.; van Swieten, J.C.; Murrell, J.R.; Ghetti, B.; Spina, S.; Grafman, J.; Hodges, J.; Spillantini, M.G.; Gilman, S.; Lieberman, A.P.; Kaye, J.A.; Woltjer, R.L.; Bigio, E.H.; Mesulam, M.; Al-Sarraj, S.; Troakes, C.; Rosenberg, R.N.; White, C.L., 3rd; Ferrer, I.; Llado, A.; Neumann, M.; Kretzschmar, H.A.; Hulette, C.M.; Welsh-Bohmer, K.A.; Miller, B.L.; Alzualde, A.; Lopez de Munain, A.; McKee, A.C.; Gearing, M.; Levey, A.I.; Lah, J.J.; Hardy, J.; Rohrer, J.D.; Lashley, T.; Mackenzie, I.R.; Feldman, H.H.; Hamilton, R.L.; Dekosky, S.T.; van der Zee, J.; Kumar-Singh, S.; Van Broeckhoven, C.; Mayeux, R.; Vonsattel, J.P.; Troncoso, J.C.; Kril, J.J.; Kwok, J.B.; Halliday, G.M.; Bird, T.D.; Ince, P.G.; Shaw, P.J.; Cairns, N.J.; Morris, J.C.; McLean, C.A.; DeCarli, C.; Ellis, W.G.; Freeman, S.H.; Frosch, M.P.; Growdon, J.H.; Perl, D.P.; Sano, M.; Bennett, D.A.; Schneider, J.A.; Beach, T.G.; Reiman, E.M.; Woodruff, B.K.; Cummings, J.; Vinters, H.V.; Miller, C.A.; Chui, H.C.; Alafuzoff, I.; Hartikainen, P.; Seilhean, D.; Galasko, D.; Masliah, E.; Cotman, C.W.; Tunon, M.T.; Martinez, M.C.; Munoz, D.G.; Carroll, S.L.; Marson, D.; Riederer, P.F.; Bogdanovic, N.; Schellenberg, G.D.; Hakonarson, H.; Trojanowski, J.Q.; Lee, V.M. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat. Genet., 2010, 42(3), 234-239.
23. DeJesus-Hernandez, M.; Mackenzie, I.R.; Boeve, B.F.; Boxer, A.L.; Baker, M.; Rutherford, N.J.; Nicholson, A.M.; Finch, N.A.; Flynn, H.; Adamson, J.; Kouri, N.; Wojtas, A.; Sengdy, P.; Hsiung, G.Y.; Karydas, A.; Seeley, W.W.; Josephs, K.A.; Coppola, G.; Geschwind, D.H.; Wszolek, Z.K.; Feldman, H.; Knopman, D.S.; Petersen, R.C.; Miller, B.L.; Dickson, D.W.; Boylan, K.B.; Graff-Radford, N.R.; Rademakers, R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron, 2011, 72(2), 245-256.
24. Renton, A.E.; Majounie, E.; Waite, A.; Simon-Sanchez, J.; Rollinson, S.; Gibbs, J.R.; Schymick, J.C.; Laaksovirta, H.; van Swieten, J.C.; Myllykangas, L.; Kalimo, H.; Paetau, A.; Abramzon, Y.; Remes, A.M.; Kaganovich, A.; Scholz, S.W.; Duckworth, J.; Ding, J.; Harmer, D.W.; Hernandez, D.G.; Johnson, J.O.; Mok, K.; Ryten, M.; Trabzuni, D.; Guerreiro, R.J.; Orrell, R.W.; Neal, J.; Murray, A.; Pearson, J.; Jansen, I.E.; Sondervan, D.; Seelaar, H.; Blake, D.; Young, K.; Halliwell, N.; Callister, J.B.; Toulson, G.; Richardson, A.; Gerhard, A.; Snowden, J.; Mann, D.; Neary, D.; Nalls, M.A.; Peuralinna, T.; Jansson, L.; Isoviita, V.M.; Kaivorinne, A.L.; Holtta-Vuori, M.; Ikonen, E.; Sulkava, R.; Benatar, M.; Wuu, J.; Chio, A.; Restagno, G.; Borghero, G.; Sabatelli, M.; Heckerman, D.; Rogaeva, E.; Zinman, L.; Rothstein, J.D.; Sendtner, M.; Drepper, C.; Eichler, E.E.; Alkan, C.; Abdullaev, Z.; Pack, S.D.; Dutra, A.; Pak, E.; Hardy, J.; Singleton, A.; Williams, N.M.; Heutink, P.; Pickering-Brown, S.; Morris, H.R.; Tienari, P.J.; Traynor, B.J. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron, 2011, 72(2), 257-268.
25. Ferraiuolo, L.; Heath, P.R.; Holden, H.; Kasher, P.; Kirby, J.; Shaw, P.J. Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. J. Neurosci., 2007, 27(34), 9201-9219.
26. Fukada, Y.; Yasui, K.; Kitayama, M.; Doi, K.; Nakano, T.; Watanabe, Y.; Nakashima, K. Gene expression analysis of the murine model of amyotrophic lateral sclerosis: studies of the Leu126delTT mutation in SOD1. Brain Res., 2007, 1160, 1-10.
27. Hensley, K.; Floyd, R.A.; Gordon, B.; Mou, S.; Pye, Q.N.; Stewart, C.; West, M.; Williamson, K. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J. Neurochem., 2002, 82(2), 365-374.
28. Lobsiger, C.S.; Boillee, S.; Cleveland, D.W. Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons. Proc. Natl. Acad. Sci. USA, 2007, 104(18), 7319-7326.
29. Yoshihara, T.; Ishigaki, S.; Yamamoto, M.; Liang, Y.; Niwa, J.; Takeuchi, H.; Doyu, M.; Sobue, G. Differential expression of inflammation-and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem., 2002, 80(1), 158-167.
30. Dangond, F.; Hwang, D.; Camelo, S.; Pasinelli, P.; Frosch, M.P.; Stephanopoulos, G.; Brown, R.H., Jr.; Gullans, S.R. Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter. Physiol. Genomics, 2004, 16(2), 229-239.
31. Ishigaki, S.; Niwa, J.; Ando, Y.; Yoshihara, T.; Sawada, K.; Doyu, M.; Yamamoto, M.; Kato, K.; Yotsumoto, Y.; Sobue, G. Differentially expressed genes in sporadic amyotrophic lateral sclerosis spinal cords--screening by molecular indexing and subsequent cDNA microarray analysis. FEBS Lett., 2002, 531(2), 354-358.
32. Malaspina, A.; Kaushik, N.; de Belleroche, J. Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J. Neurochem., 2001, 77(1), 132-145.
33. Offen, D.; Barhum, Y.; Melamed, E.; Embacher, N.; Schindler, C.; Ransmayr, G. Spinal cord mRNA profile in patients with ALS: comparison with transgenic mice expressing the human SOD-1 mutant. J. Mol. Neurosci., 2009, 38(2), 85-93.
34. Jiang, Y.M.; Yamamoto, M.; Kobayashi, Y.; Yoshihara, T.; Liang, Y.; Terao, S.; Takeuchi, H.; Ishigaki, S.; Katsuno, M.; Adachi, H.; Niwa, J.; Tanaka, F.; Doyu, M.; Yoshida, M.; Hashizume, Y.; Sobue, G. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann.Neurol., 2005, 57(2), 236-251.
35. Wang, X.S.; Simmons, Z.; Liu, W.; Boyer, P.J.; Connor, J.R. Differential expression of genes in amyotrophic lateral sclerosis revealed by profiling the post mortem cortex. Amyotroph. Lateral. Scler., 2006, 7(4), 201-210.
36. Lederer, C.W.; Torrisi, A.; Pantelidou, M.; Santama, N.; Cavallaro, S. Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis. BMC Genomics, 2007, 8(1), 26.
37. Kudo, L.C.; Parfenova, L.; Vi, N.; Lau, K.; Pomakian, J.; Valdmanis, P.; Rouleau, G.A.; Vinters, H.V.; Wiedau-Pazos, M.; Karsten, S.L. Integrative gene-tissue microarray-based approach for identification of human disease biomarkers: application to amyotrophic lateral sclerosis. Hum. Mol. Genet., 2010, 19(16), 3233-3253.
38. Petri, S.; Krampfl, K.; Hashemi, F.; Grothe, C.; Hori, A.; Dengler, R.; Bufler, J. Distribution of GABAA receptor mRNA in the motor cortex of ALS patients. J. Neuropathol. Exp. Neurol., 2003, 62(10), 1041-1051.
39. de Carvalho Aguiar, P.; Sweadner, K.J.; Penniston, J.T.; Zaremba, J.; Liu, L.; Caton, M.; Linazasoro, G.; Borg, M.; Tijssen, M.A.; Bressman, S.B.; Dobyns, W.B.; Brashear, A.; Ozelius, L.J. Mutations in the Na+/K+-ATPase alpha3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism. Neuron, 2004, 43(2), 169-175.
40. Ellis, D.Z.; Rabe, J.; Sweadner, K.J. Global loss of Na,K-ATPase and its nitric oxide-mediated regulation in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci., 2003, 23(1), 43-51.
41. Gonzalez Deniselle, M.C.; Lopez-Costa, J.J.; Saavedra, J.P.; Pietranera, L.; Gonzalez, S.L.; Garay, L.; Guennoun, R.; Schumacher, M.; De Nicola, A.F. Progesterone neuroprotection in the Wobbler mouse, a genetic model of spinal cord motor neuron disease. Neurobiol. Dis., 2002, 11(3), 457-468.
42. Wang, J.W.; Humphreys, J.M.; Phillips, J.P.; Hilliker, A.J.; Wu, C.F. A novel leg-shaking Drosophila mutant defective in a voltage-gated K(+)current and hypersensitive to reactive oxygen species. J. Neurosci., 2000, 20(16), 5958-5964.
43. Blaesse, P.; Airaksinen, M.S.; Rivera, C.; Kaila, K. Cation-chloride cotransporters and neuronal function. Neuron, 2009, 61(6), 820-838
44. Rivera, C.; Voipio, J.; Payne, J.A.; Ruusuvuori, E.; Lahtinen, H.; Lamsa, K.; Pirvola, U.; Saarma, M.; Kaila, K. The K+/Cl-co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature, 1999, 397(6716), 251-255.
45. Toyoda, H.; Ohno, K.; Yamada, J.; Ikeda, M.; Okabe, A.; Sato, K.; Hashimoto, K.; Fukuda, A. Induction of NMDA and GABAA receptor-mediated Ca2+ oscillations with KCC2 mRNA downregulation in injured facial motoneurons. J. Neurophysiol., 2003, 89(3), 1353-1362.
46. Nabekura, J.; Ueno, T.; Okabe, A.; Furuta, A.; Iwaki, T.; Shimizu-Okabe, C.; Fukuda, A.; Akaike, N. Reduction of KCC2 expression and GABAA receptor-mediated excitation after in vivo axonal injury. J. Neurosci., 2002, 22(11), 4412-4417.
47. Hubner, C.A.; Stein, V.; Hermans-Borgmeyer, I.; Meyer, T.; Ballanyi, K.; Jentsch, T.J. Disruption of KCC2 reveals an essential role of K-Cl cotransport already in early synaptic inhibition. Neuron, 2001, 30(2), 515-524.
48. Roth, F.P.; Lipshitz, H.D.; Andrews, B.J. Q&A: epistasis. J. Biol., 2009, 8(4), 35.
49. Harris, M.A.; Clark, J.; Ireland, A.; Lomax, J.; Ashburner, M.; Foulger, R.; Eilbeck, K.; Lewis, S.; Marshall, B.; Mungall, C.; Richter, J.; Rubin, G.M.; Blake, J.A.; Bult, C.; Dolan, M.; Drabkin, H.; Eppig, J.T.; Hill, D.P.; Ni, L.; Ringwald, M.; Balakrishnan, R.; Cherry, J.M.; Christie, K.R.; Costanzo, M.C.; Dwight, S.S.; Engel, S.; Fisk, D.G.; Hirschman, J.E.; Hong, E.L.; Nash, R.S.; Sethuraman, A.; Theesfeld, C.L.; Botstein, D.; Dolinski, K.; Feierbach, B.; Berardini, T.; Mundodi, S.; Rhee, S.Y.; Apweiler, R.; Barrell, D.; Camon, E.; Dimmer, E.; Lee, V.; Chisholm, R.; Gaudet, P.; Kibbe, W.; Kishore, R.; Schwarz, E.M.; Sternberg, P.; Gwinn, M.; Hannick, L.; Wortman, J.; Berriman, M.; Wood, V.; de la Cruz, N.; Tonellato, P.; Jaiswal, P.; Seigfried, T.; White, R. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res., 2004, 32(Database issue), D258-261.
50. Kanehisa, M. The KEGG database. Novartis Found. Symp., 2002, 247, 91-101; discussion 101-103, 119-128, 244-152.
51. Dahlquist, K.D.; Salomonis, N.; Vranizan, K.; Lawlor, S.C.; Conklin, B.R. GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat. Genet., 2002, 31(1), 19-20.
52. Shaw, P.J. Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol. Neurosurg. Psychiatry, 2005, 76(8), 1046-1057.
53. Zhao, C.; Takita, J.; Tanaka, Y.; Setou, M.; Nakagawa, T.; Takeda, S.; Yang, H.W.; Terada, S.; Nakata, T.; Takei, Y.; Saito, M.; Tsuji, S.; Hayashi, Y.; Hirokawa, N. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell, 2001, 105(5), 587-597.
54. Reid, E.; Kloos, M.; Ashley-Koch, A.; Hughes, L.; Bevan, S.; Svenson, I.K.; Graham, F.L.; Gaskell, P.C.; Dearlove, A.; Pericak-Vance, M.A.; Rubinsztein, D.C.; Marchuk, D.A. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am. J. Hum. Genet., 2002, 71(5), 1189-1194.
55. Hurd, D.D.; Saxton, W.M. Kinesin mutations cause motor neuron disease phenotypes by disrupting fast axonal transport in Drosophila. Genetics, 1996, 144(3), 1075-1085.
56. LaMonte, B.H.; Wallace, K.E.; Holloway, B.A.; Shelly, S.S.; Ascano, J.; Tokito, M.; Van Winkle, T.; Howland, D.S.; Holzbaur, E.L. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron, 2002, 34(5), 715-727.
57. Williamson, T.L.; Bruijn, L.I.; Zhu, Q.; Anderson, K.L.; Anderson, S.D.; Julien, J.P.; Cleveland, D.W. Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. Proc. Natl. Acad. Sci. U S A, 1998, 95(16), 9631-9636.
58. Couillard-Despres, S.; Zhu, Q.; Wong, P.C.; Price, D.L.; Cleveland, D.W.; Julien, J.P. Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase. Proc. Natl. Acad. Sci. U S A, 1998, 95(16), 9626-9630.
59. Bruijn, L.I.; Beal, M.F.; Becher, M.W.; Schulz, J.B.; Wong, P.C.; Price, D.L.; Cleveland, D.W. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Proc. Natl. Acad. Sci. U S A, 1997, 94(14), 7606-7611.
60. Julien, J.P.; Beaulieu, J.M. Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects? J. Neurol. Sci., 2000, 180(1-2), 7-14.
61. Williamson, T.L.; Cleveland, D.W. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat. Neurosci., 1999, 2(1), 50-56.
62. Costanzo, M.; Baryshnikova, A.; Bellay, J.; Kim, Y.; Spear, E.D.; Sevier, C.S.; Ding, H.; Koh, J.L.; Toufighi, K.; Mostafavi, S.; Prinz, J.; St Onge, R.P.; VanderSluis, B.; Makhnevych, T.; Vizeacoumar, F.J.; Alizadeh, S.; Bahr, S.; Brost, R.L.; Chen, Y.; Cokol, M.; Deshpande, R.; Li, Z.; Lin, Z.Y.; Liang, W.; Marback, M.; Paw, J.; San Luis, B.J.; Shuteriqi, E.; Tong, A.H.; van Dyk, N.; Wallace, I.M.; Whitney, J.A.; Weirauch, M.T.; Zhong, G.; Zhu, H.; Houry, W.A.; Brudno, M.; Ragibizadeh, S.; Papp, B.; Pal, C.; Roth, F.P.; Giaever, G.; Nislow, C.; Troyanskaya, O.G.; Bussey, H.; Bader, G.D.; Gingras, A.C.; Morris, Q.D.; Kim, P.M.; Kaiser, C.A.; Myers, C.L.; Andrews, B.J.; Boone, C. The genetic landscape of a cell. Science, 2010, 327(5964), 425-431.
63. Sauer, U.; Heinemann, M.; Zamboni, N. Genetics. Getting closer to the whole picture. Science, 2007, 316(5824), 550-551.
64. Seeley, W.W.; Crawford, R.K.; Zhou, J.; Miller, B.L.; Greicius, M.D. Neurodegenerative diseases target large-scale human brain networks. Neuron, 2009, 62(1), 42-52.
65. Limviphuvadh, V.; Tanaka, S.; Goto, S.; Ueda, K.; Kanehisa, M. The commonality of protein interaction networks determined in neurodegenerative disorders (NDDs). Bioinformatics, 2007, 23(16), 2129-2138.
66. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today, 2004, 9(15), 641-651.
67. Stark, C.; Breitkreutz, B.J.; Chatr-Aryamontri, A.; Boucher, L.; Oughtred, R.; Livstone, M.S.; Nixon, J.; Van Auken, K.; Wang, X.; Shi, X.; Reguly, T.; Rust, J.M.; Winter, A.; Dolinski, K.; Tyers, M. The BioGRID Interaction Database: 2011 update. Nucleic Acids Res., 2011, 39(Database issue), D698-704.
68. Ceol, A.; Chatr Aryamontri, A.; Licata, L.; Peluso, D.; Briganti, L.; Perfetto, L.; Castagnoli, L.; Cesareni, G. MINT, the molecular interaction database: 2009 update. Nucleic Acids Res., 2010, 38(Database issue), D532-539.
69. Ekins, S.; Bugrim, A.; Brovold, L.; Kirillov, E.; Nikolsky, Y.; Rakhmatulin, E.; Sorokina, S.; Ryabov, A.; Serebryiskaya, T.; Melnikov, A.; Metz, J.; Nikolskaya, T. Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platforms. Xenobiotica, 2006, 36(10-11), 877-901.
70. Goel, R.; Muthusamy, B.; Pandey, A.; Prasad, T.S. Human protein reference database and human proteinpedia as discovery resources for molecular biotechnology. Mol. Biotechnol., 2011, 48(1), 87-95.
71. Salwinski, L.; Miller, C.S.; Smith, A.J.; Pettit, F.K.; Bowie, J.U.; Eisenberg, D. The Database of Interacting Proteins: 2004 update. Nucleic Acids Res., 2004, 32(Database issue), D449-451.
72. Palmiter, R.D. The elusive function of metallothioneins. Proc. Natl. Acad. Sci. U S A, 1998, 95(15), 8428-8430.
73. Kelly, E.J.; Quaife, C.J.; Froelick, G.J.; Palmiter, R.D. Metallothionein I and II protect against zinc deficiency and zinc toxicity in mice. J. Nutr., 1996, 126(7), 1782-1790.
74. Kim, J.; Kim, T.Y.; Hwang, J.J.; Lee, J.Y.; Shin, J.H.; Gwag, B.J.; Koh, J.Y. Accumulation of labile zinc in neurons and astrocytes in the spinal cords of G93A SOD-1 transgenic mice. Neurobiol. Dis., 2009, 34(2), 221-229.
75. Liu, Y.; Liu, J.; Iszard, M.B.; Andrews, G.K.; Palmiter, R.D.; Klaassen, C.D. Transgenic mice that overexpress metallothionein-I are protected from cadmium lethality and hepatotoxicity. Toxicol. Appl. Pharmacol., 1995, 135(2), 222-228.
76. Taylor, D.M.; Minotti, S.; Agar, J.N.; Durham, H.D. Overexpression of metallothionein protects cultured motor neurons against oxidative stress, but not mutant Cu/Zn-superoxide dismutase toxicity. Neurotoxicology, 2004, 25(5), 779-792.
77. Chung, R.S.; Penkowa, M.; Dittmann, J.; King, C.E.; Bartlett, C.; Asmussen, J.W.; Hidalgo, J.; Carrasco, J.; Leung, Y.K.; Walker, A.K.; Fung, S.J.; Dunlop, S.A.; Fitzgerald, M.; Beazley, L.D.; Chuah, M.I.; Vickers, J.C.; West, A.K. Redefining the role of metallothionein within the injured brain: extracellular metallothioneins play an important role in the astrocyte-neuron response to injury. J. Biol. Chem., 2008, 283(22), 15349-15358.
78. Fauman, E.B.; Rai, B.K.; Huang, E.S. Structure-based druggability assessment-identifying suitable targets for small molecule therapeutics. Curr. Opin. Chem. Biol., 2011, 15(4), 463-468.
79. Hopkins, A.L.; Groom, C.R. The druggable genome. Nat. Rev. Drug Discov., 2002, 1(9), 727-730.
80. Yildirim, M.A.; Goh, K.I.; Cusick, M.E.; Barabasi, A.L.; Vidal, M. Drug-target network. Nat. Biotechnol., 2007, 25(10), 1119-1126.
81. Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A.C.; Wishart, D.S. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res., 2011, 39(Database issue), D1035-1041.
82. Zhu, F.; Han, B.; Kumar, P.; Liu, X.; Ma, X.; Wei, X.; Huang, L.; Guo, Y.; Han, L.; Zheng, C.; Chen, Y. Update of TTD: Therapeutic Target Database. Nucleic Acids Res., 2010, 38(Database issue), D787-791.
83. Thorn, C.F.; Klein, T.E.; Altman, R.B. Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics, 2010, 11(4), 501-505.
84. Kuhn, M.; Szklarczyk, D.; Franceschini, A.; Campillos, M.; von Mering, C.; Jensen, L.J.; Beyer, A.; Bork, P. STITCH 2: an interaction network database for small molecules and proteins. Nucleic Acids Res., 2010, 38(Database issue), D552-556.
85. Gunther, S.; Kuhn, M.; Dunkel, M.; Campillos, M.; Senger, C.; Petsalaki, E.; Ahmed, J.; Urdiales, E.G.; Gewiess, A.; Jensen, L.J.; Schneider, R.; Skoblo, R.; Russell, R.B.; Bourne, P.E.; Bork, P.; Preissner, R. SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res., 2008, 36(Database issue), D919-922.
86. Suzuki, S.; Masui, Y.; Ohnuki, M.; Miyakoda, G.; Mori, T.; Nakajima, K.; Sato, M. Induction of metallothionein synthesis by cilostazol in mice and in human cultured neuronal cell lines. Biol. Pharm. Bull., 2007, 30(4), 791-794.
87. Wakida, K.; Morimoto, N.; Shimazawa, M.; Hozumi, I.; Nagase, H.; Inuzuka, T.; Hara, H. Cilostazol reduces ischemic brain damage partly by inducing metallothionein-1 and-2. Brain Res., 2006, 1116(1), 187-193.
88. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 2004, 3(8), 711-715.
89. Zhou, H.; Huang, C.; Chen, H.; Wang, D.; Landel, C.P.; Xia, P.Y.; Bowser, R.; Liu, Y.J.; Xia, X.G. Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet., 2010, 6(3), e1000887.
90. Xu, Y.F.; Gendron, T.F.; Zhang, Y.J.; Lin, W.L.; D'Alton, S.; Sheng, H.; Casey, M.C.; Tong, J.; Knight, J.; Yu, X.; Rademakers, R.; Boylan, K.; Hutton, M.; McGowan, E.; Dickson, D.W.; Lewis, J.; Petrucelli, L. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J. Neurosci., 2010, 30(32), 10851-10859.
91. Huang, C.; Zhou, H.; Tong, J.; Chen, H.; Liu, Y.J.; Wang, D.; Wei, X.; Xia, X.G. FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. PLoS Genet., 2011, 7(3), e1002011.
92. Swarup, V.; Julien, J.P. ALS pathogenesis: Recent insights from genetics and mouse models. Prog Neuropsychopharmacol. Biol. Psychiatry, 2010.
93. Pioro, E.P.; Mitsumoto, H. Animal models of ALS. Clin. Neurosci., 1995, 3(6), 375-385.
94. Doble, A.; Kennel, P. Animal models of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord., 2000, 1(5), 301-312.
95. Cai, H.; Shim, H.; Lai, C.; Xie, C.; Lin, X.; Yang, W.J.; Chandran, J. ALS2/alsin knockout mice and motor neuron diseases. Neurodegener. Dis., 2008, 5(6), 359-366.
96. Wegorzewska, I.; Bell, S.; Cairns, N.J.; Miller, T.M.; Baloh, R.H. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. U S A, 2009, 106(44), 18809-18814.
97. Barrett, T.; Edgar, R. Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Methods Enzymol., 2006, 411, 352-369.
98. Parkinson, H.; Sarkans, U.; Kolesnikov, N.; Abeygunawardena, N.; Burdett, T.; Dylag, M.; Emam, I.; Farne, A.; Hastings, E.; Holloway, E.; Kurbatova, N.; Lukk, M.; Malone, J.; Mani, R.; Pilicheva, E.; Rustici, G.; Sharma, A.; Williams, E.; Adamusiak, T.; Brandizi, M.; Sklyar, N.; Brazma, A. ArrayExpress update--an archive of microarray and high-throughput sequencing-based functional genomics experiments. Nucleic Acids Res., 2011, 39(Database issue), D1002-1004.
99. Hopkins, A.L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol., 2008, 4(11), 682-690.